Table 1.

Baseline characteristics, pathological findings and outcomes in the whole population of patients stratified by RDW level and their correlation with RDW.

	Whole population n = 74	RDW
		Low (<13.5%) n = 28	High (≥13.5%) n = 46	p-value
Sex (% of males)	79,73%	82,14%	78,26%	0.69
Age [years]	60,7 (40.7−83.0)	59,8 (49.6−76.4)	61,2 (40.7−83.0)	0.47
RDW [%]	13.9 (12.0−16.3)	12,8 (12,0−13.4)	14,5 (13.5−16.3)
Hemoglobin [g/dl]	13.8 (10.3−18.5)	14.0 (11.0−15.9)	13.7 (10.3−18.5)	0.23
Hematocrit [%]	40,3 (30.8−54.6)	41,2 (33.1−47.2)	39.8 (30.8−54.6)	0.1
RBC (106/mm3)	4.38 (3.56−5.64)	4.43 (3.68−5.21)	4.35 (3.56−5.64)	0.31
WBC (103/mm3)	8.3 (5−15)	8.2 (5.4−14.5)	8.4 (5−15)	0.86
TNM T stage				0.84
1	2.7%	3.6%	2.2%
2	24.3%	17.8%	28.3%
3	18.9%	25%	15.2%
4	54.1%	53.6%	54.3%
TNM N stage				0.37
0	25.7%	28.6%	23.9%
1	18.9%	25%	15.2%
2	47.3%	39.3%	52.2%
3	8.1%	7.1%	8.7%
Tumor volume				0.5
<15cc	28.4%	28.6%	28.3%
15−30cc	31.1%	35.7%	28.3%
>30cc	40.5%	35.7%	43.4%
% base of tongue	75.7%	78.6%	73.9%	0.65
Concomitant diseases	58.1%	50%	62%	0.30
History of smoking				0.29
Non-smoker	11%	17.9%	6.7%
Former smoker	6.8%	7.1%	6.7%
Active smoker	82.2%	75%	86.6%
Pack-years	32.5 (0−105)	27.6 (0−90)	35.6 (0−105)	0.07
History of alcohol abuse	17.8%	17.9%	17.8%	0.99
ZUBROD				0.97
0−1	93,2	89,3%	95,6%
2	5.4%	10.7%	2.2%
3+	1.4%	0%	2.2%
Fractionation regimen:				0.01
Conventional	48.6%	64.3%	39.1%
CAIR31	27%	28.6%	26.1%
CHA-CHA32	19%	7.1%	26.1%
EBRT + BT	5.4%	0%	8.7%
Addition of chemotherapy	27%	36%	22%	0.19
Type of chemotherapy				0.12
Neoadjuvant	25%	20%	30%
Concomitant	40%	40%	40%
Both	35%	40%	30%
5-year OSa	42%	67%	26%	0,0005

Continuous variables are presented as mean (min-max range) unless indicated otherwise. Dichotomous variables are presented as percentages.

^alog-rank.